ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

OLMA Olema Pharmaceuticals Inc

9.78
-0.06 (-0.61%)
11 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Olema Pharmaceuticals Inc NASDAQ:OLMA NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.06 -0.61% 9.78 9.12 15.00 10.02 9.1601 9.89 606,720 05:00:09

Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference

02/01/2024 9:01pm

GlobeNewswire Inc.


Olema Pharmaceuticals (NASDAQ:OLMA)
Historical Stock Chart


From Nov 2023 to May 2024

Click Here for more Olema Pharmaceuticals Charts.

Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that Sean P. Bohen, M.D., President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Tuesday, January 9, 2024, at 5:15 p.m. PT (8:15 p.m. ET).

A live webcast of the presentation and any accompanying presentation materials will be available under the News & Events section of Olema’s investor relations website at ir.olema.com. The webcast will be archived for at least 30 days. 

About Olema OncologyOlema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, palazestrant (OP-1250), is a proprietary, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated both as a single agent in an ongoing Phase 3 clinical trial, OPERA-01, and in combination with CDK4/6 inhibitors (palbociclib and ribociclib) and a PI3Ka inhibitor (alpelisib), in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Palazestrant has been granted FDA Fast Track designation for the treatment of ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at www.olema.com.

Contact:Geoffrey Mogilner, Vice President, Investor Relations and Communicationsir@olema.com

 

1 Year Olema Pharmaceuticals Chart

1 Year Olema Pharmaceuticals Chart

1 Month Olema Pharmaceuticals Chart

1 Month Olema Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock